

# Raul E Isturiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9134209/publications.pdf>

Version: 2024-02-01

23  
papers

686  
citations

687363

13  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. <i>JAMA Network Open</i> , 2022, 5, e221111.	5.9	26
2	The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia. <i>Expert Review of Vaccines</i> , 2021, 20, 269-280.	4.4	15
3	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 1216-1222.	5.8	33
4	The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. <i>Expert Review of Vaccines</i> , 2021, 20, 691-705.	4.4	14
5	One-Year Quality of Life Post“Pneumonia Diagnosis in Japanese Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 283-290.	5.8	20
6	US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 244-247.	1.3	20
7	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2758-2772.	3.3	7
8	<i>Streptococcus pneumoniae</i> serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009“2017. <i>Journal of Infection</i> , 2020, 81, 557-566.	3.3	33
9	Lessons from mass vaccination response to meningococcal B outbreaks at US universities. <i>Postgraduate Medicine</i> , 2020, 132, 614-623.	2.0	8
10	Diabetes mellitus as a vaccine-effect modifier: a review. <i>Expert Review of Vaccines</i> , 2020, 19, 445-453.	4.4	20
11	Upper respiratory tract colonization with <i>Streptococcus pneumoniae</i> in adults. <i>Expert Review of Vaccines</i> , 2020, 19, 353-366.	4.4	31
12	Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not. <i>Postgraduate Medicine</i> , 2019, 131, 551-554.	2.0	1
13	Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. <i>Vaccine</i> , 2019, 37, 6310-6316.	3.8	43
14	Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 841-849.	3.3	29
15	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. <i>Vaccine</i> , 2019, 37, 3352-3361.	3.8	54
16	Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2205-2216.	3.3	9
17	2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, S953-S954.	0.9	3
18	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. <i>Clinical Infectious Diseases</i> , 2019, 68, 2135-2143.	5.8	70

#	ARTICLE	IF	CITATIONS
19	Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. <i>Vaccine</i> , 2018, 36, 7479-7486.	3.8	52
20	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. <i>Clinical Infectious Diseases</i> , 2018, 67, 1498-1506.	5.8	98
21	Response to Mungall et al. letter to the editor on <i>Streptococcus pneumoniae</i> serotype 19A: worldwide epidemiology. <i>Expert review of vaccines</i> 2017;16(10):1007–27. <i>Expert Review of Vaccines</i> , 2018, 17, 669-671.	4.4	2
22	Response to Effectiveness of the 10-Valent Pneumococcal Nontypeable <i>Haemophilus influenzae</i> Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, piw074.	1.3	0
23	<i>Streptococcus pneumoniae</i> serotype 19A: worldwide epidemiology. <i>Expert Review of Vaccines</i> , 2017, 16, 1007-1027.	4.4	98